Delivery Order SPE2DB20D2002-SPE2DB25FL44J

Award Date 5/21/25
Potential Completion Date 5/22/25
Potential Value $114K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award is for the delivery of the pharmaceutical product HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML to the Defense Logistics Agency (DLA). The fixed-price delivery order, valued at $8,856.30, was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, on May 14, 2025. The contract has an ultimate completion date of May 15, 2025 and is not designated as a set-aside. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA...
This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, is a delivery order valued at $153,284 for the supply of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML. The contract was awarded by the Defense Logistics Agency (DLA), a defense agency, and has an ultimate completion date of August 4, 2023. The contract is a firm fixed-price arrangement, and there is no set-aside designation indicated. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC)...
This federal contract award to Amerisourcebergen Drug Corp is a $5,126.16 delivery order for the product HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML. The contract has an ultimate completion date of August 26, 2024 and was awarded on August 23, 2024. The contract is a firm fixed price arrangement with the Defense Logistics Agency (DLA), a defense agency within the Department of Defense. Amerisourcebergen is a major pharmaceutical distributor and healthcare solutions provider that plays a critical role...
Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, has been awarded a $7,886.40 firm fixed price delivery order contract by the Defense Logistics Agency (DLA) to provide HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a pharmaceutical product, with a completion date of February 12, 2024. This delivery order is part of an indefinite delivery contract (IDC) valued at up to $999,999,999.00 awarded to Amerisourcebergen Drug Corp by DLA, which serves as the primary vehicle for the...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract worth $7,148.05 to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide the HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML pharmaceutical product. The contract has an ultimate completion date of March 25, 2024 and does not utilize any set-aside designation. Amerisourcebergen Drug Corp holds an indefinite delivery contract with DLA valued up to $999,999,999.00 through December 31,...
This is a firm fixed price delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of the leading global pharmaceutical distributor Amerisourcebergen Corporation. The $27,996.72 contract is for the supply of the pharmaceutical product HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, with a completion date of March 4, 2024. Amerisourcebergen Drug Corp, a for-profit organization, serves as a prime contractor providing a wide range of pharmaceutical products...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp's Corporate Office Division. The $2,164.49 firm fixed price delivery order is for the pharmaceutical product HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML. The award has an ultimate completion date of April 22, 2024. Amerisourcebergen Drug Corp holds a $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as the primary vehicle for the company to...
This federal contract award is a delivery order valued at $1,263.72 awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, with a completion date of May 22, 2025. This contract is not set aside and was competitively awarded. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop...
The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the supply of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML. The $1,577.28 award has a completion date of February 13, 2024. Amerisourcebergen Drug Corp is the prime contractor on an indefinite delivery contract (IDC) with DLA, valued at up to $999,999,999.00, that serves as the primary vehicle for the company to deliver pharmaceutical products...
The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML pharmaceutical products. The order has a completion date of February 8, 2024 and a potential value of $1,577.28. Amerisourcebergen Drug Corp is the prime contractor on this delivery order, which is not associated with any set-aside designation. Additionally, Amerisourcebergen Drug Corp holds...
  • SPE2DB20D2002
    Indefinite Delivery Contract
  • SPE2DB20D2002-SPE2DB25FL44J
    Delivery Order

This federal contract award to Amerisourcebergen Drug Corp is for the pharmaceutical product HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML. The $113,657.00 firm fixed price delivery order was awarded by the Defense Logistics Agency (DLA), a defense agency. The contract has an ultimate completion date of May 22, 2025 and is not set aside.

Amerisourcebergen Drug Corp is a major pharmaceutical distributor that serves as a critical supplier of medical and pharmaceutical products to federal agencies, including the DLA. The company holds a $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, providing a comprehensive global pharmaceutical support vehicle through December 2026. This latest delivery order is likely part of the company's broader efforts to fulfill varied federal medical supply requirements, particularly for military and veteran healthcare systems, through its IDC and other contract vehicles.

Generated 8/20/25, 9:55 AM